OncoMatch/Clinical Trials/NCT06476808
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Is NCT06476808 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BMS-986463 for high-grade serous ovarian carcinoma (hgsoc).
Treatment: BMS-986463 — The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- Valkyrie Clinical Trials · Los Angeles, California
- John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, New Jersey
- Local Institution - 0045 · Columbus, Ohio
- Local Institution - 0046 · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify